[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100534112":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":31,"centralContacts":40,"locations":46,"responsibleParty":62,"collaborators":64,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":72,"sex":78,"minAge":79,"maxAge":31,"enrollmentInfo":80,"targetDuration":31,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":31,"overallStatus":49,"whyStopped":31,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"King's College Hospital NHS Trust","OTHER",[8,15,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Angiotensin II Infusion","EXPERIMENTAL","Angiotensin II infusion commenced alongside standard care vasopressor therapy (norepinephrine). Angiotensin II up titrated in a protocolised manner to a target\u002Fmaximum dose of 40 ng\u002Fkg\u002Fmin whilst noradrenaline down titrated in order to achieve\u002Fmaintain target mean arterial pressure (MAP) as directed by attending clinician.",[13,14],"Drug: Angiotensin II","Drug: Norepinephrine",{"label":16,"type":10,"description":17,"interventionNames":18},"Vasopressin Infusion","Vasopressin infusion commenced alongside standard care vasopressor therapy (norepinephrine). Vasopressin up titrated in a protocolised manner to a target\u002Fmaximum dose of 0.04 IU\u002Fmin whilst noradrenaline down titrated in order to achieve\u002Fmaintain target mean arterial pressure (MAP) as directed by attending clinician.",[19,14],"Drug: Vasopressin",{"label":21,"type":22,"description":23,"interventionNames":24},"Norepinephrine Infusion","ACTIVE_COMPARATOR","Standard care vasopressor therapy which recruited participants already receiving, titrated to achieve\u002Fmaintain target mean arterial pressure (MAP) as directed by attending clinician.",[14],[26,32,36],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","Angiotensin II","Angiotensin II infusion",[9],null,{"type":27,"name":33,"description":34,"armGroupLabels":35,"otherNames":31},"Vasopressin","Vasopressin infusion",[16],{"type":27,"name":37,"description":38,"armGroupLabels":39,"otherNames":31},"Norepinephrine","Standard care vasopressor therapy, norepinephrine infusion",[9,21,16],[41],{"name":42,"role":43,"phone":44,"phoneExt":31,"email":45},"Sam Hutchings","CONTACT","02032994957","sam.hutchings@nhs.net",[47],{"facility":48,"status":49,"city":50,"state":31,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"King's College Hospital","RECRUITING","London","SE5 9RS","United Kingdom","UK",{"type":55,"coordinates":56},"Point",[57,58],-0.12574,51.50853,{"lat":58,"lon":57},[61],{"name":42,"role":43,"phone":44,"phoneExt":31,"email":45},{"type":63,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR",[65,67],{"name":66,"class":6},"European Society of Intensive Care Medicine",{"name":68,"class":69},"Royal Centre for Defence Medicine","OTHER_GOV","100534112","the-effect-of-vasopressor-therapy-on-renal-perfusion-in-septic-shock-100534112",false,"NCT06234592","The Effect of Vasopressor Therapy on Renal Perfusion in Septic Shock","The Effect of Vasopressor Therapy on Renal Perfusion in Patients With Septic Shock - a Mechanistically Focussed Randomized Control Study","REPERFUSE","Inclusion Criteria:\n\n* Within 48 hours of intensive care admission\n* Evidence of suspected or confirmed infection\n* Sequential Organ Failure (SOFA) score increase of 2 or more (assuming a baseline of 0 if no previous measures)\n* Requirement for norepinephrine infusion as the sole vasopressor agent in a dose of \\>0.1mcg\u002Fkg\u002Fmin\n* Lactate \\>2mmol\u002FL at any stage prior to randomisation\n\nExclusion Criteria:\n\n* Known intolerance to Sonovue™ contrast medium, vasopressin or angiotensin II\n* Patients receiving other vasoactive drugs in addition to norepinephrine\n* Patients with known chronic kidney disease (CKD) stage 4 or 5 (baseline glomerular filtration rate (GFR) \\\u003C30mls\u002Fmin)\n* Patients receiving extra corporal membrane oxygenation (ECMO)\n* Patients with acute occlusive coronary syndromes requiring intervention\n* Patients with mesenteric ischaemia\n* Patients with a history or presence of aortic dissection or abdominal aortic aneurysm\n* Patients with Raynaud's syndrome or acute vaso-occlusive conditions\n* Pregnancy","ALL","18 Years",{"count":81,"type":82},45,"ESTIMATED","INTERVENTIONAL",[85],"NA","Acute kidney injury (AKI) is a common complication of septic shock and together these conditions carry a high mortality risk. In septic patients who develop severe AKI renal cortical perfusion is deficient despite normal macrovascular organ blood flow. This intra-renal perfusion abnormality may be amenable to pharmacological manipulation, which may offer mechanistic insight into the pathophysiology of septic AKI. The aim of the current study is to investigate the effects of vasopressin and angiotensin II on renal microcirculatory perfusion in a cohort of patients with septic shock.",[88,89],"Septic Shock","Acute Kidney Injury","2025-04-01",{"date":92,"type":93},"2025-04-04","ACTUAL",{"date":95,"type":93},"2024-01-05",{"date":97,"type":82},"2026-07",{"name":5,"class":6},1]